MasterClass memberships are 40 percent off right now
You could watch a class on writing taught by James Patterson, or learn cooking techniques from Thomas Keller. If you're trying to impress at your next pickup basketball game you could learn about shooting, ball-handling and scoring from Steph Curry. Each class includes around 20 video lessons that run about 10 minutes long on average, as well as an in-depth workbook.
MasterClass has also begun producing some original series for its platform. The series Business Rebels features different CEOs walking viewers through the strategies that helped them disrupt their industries. One entitled Skin Health features top dermatologists and a cosmetic chemist walking viewers through keeping their skin healthy through cleansing routines and specific beauty products.
The wide range of skills or life lessons you could learn through these classes is why MasterClass is on our list of best subscriptions you can give as gifts . Maybe your loved one who loves to host dinner parties could use some tips from Gordon Ramsay.
There are three subscription tiers for MasterClass that each differ only in how many devices they allow at one time, and whether offline videos are supported. The Standard subscription only supports one device, whereas the Plus subscription allows two. These are normally $10 and $15 per month, respectively, and neither offers offline mode. The Premium tier, which carries a regular price of $20 per month, allows up to six devices and features offline mode for downloaded classes.
All three tiers are part of the 40 percent off sale, which marks them down to $6, $9 and $12 respectively. MasterClass bills annually, so be sure to calculate the total from the "monthly" price before deciding.
Follow @EngadgetDeals on X for the latest tech deals and buying advice .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares. The increase reflects the acquisition by Paulson Capital Inc. and certain affiliates and managed funds of the net long position of 34,721,118 common shares previously held by Mr. Carl C. Icahn and his affiliates (collectively, "Icahn Group"). The Company is not a party to any agreement or arrangement with Paulson Capital Inc. or its affiliates or the Icahn Group in connection with these transactions. Based on information provided to the Company, Paulson Capital Inc. and certain affiliates and managed funds beneficially owns approximately 19.13% of the Company's outstanding common shares as of the date hereof. The Company further announced that the Director Appointment and Nomination Agreement, dated as of February 23, 2021, between the Company and Icahn Group, terminated pursuant to its terms when the Icahn Group's net long position in the Company's shares fell below the specified threshold. In connection with the termination, Brett M. Icahn and Steven D. Miller have resigned from the Board of Directors (the "Board"). "I believe there is significant value in Bausch Health and am confident in the Company's efforts to maximize shareholder value. I am excited about the underlying business prospects in both Bausch Health and its subsidiary, Bausch + Lomb Corporation," John A. Paulson, Chairperson of the Bausch Health Board, said. "I also want to thank Brett and Steven for their dedication and valuable contributions to the Company." About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit and connect with us on LinkedIn. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@ (877) 281-6642 (toll free) (908) 569-3692 SOURCE: Bausch Health Companies Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Engadget
16 hours ago
- Engadget
MasterClass memberships are 40 percent off right now
MasterClass promises online learning with instructors who are the very best in their fields, and an annual subscription is currently 40 percent off across all tiers. Subscribers to MasterClass will have access to over 200 classes taught by iconic authors, chefs, athletes and leaders representing a diverse collection of skill sets and backgrounds. You could watch a class on writing taught by James Patterson, or learn cooking techniques from Thomas Keller. If you're trying to impress at your next pickup basketball game you could learn about shooting, ball-handling and scoring from Steph Curry. Each class includes around 20 video lessons that run about 10 minutes long on average, as well as an in-depth workbook. MasterClass has also begun producing some original series for its platform. The series Business Rebels features different CEOs walking viewers through the strategies that helped them disrupt their industries. One entitled Skin Health features top dermatologists and a cosmetic chemist walking viewers through keeping their skin healthy through cleansing routines and specific beauty products. The wide range of skills or life lessons you could learn through these classes is why MasterClass is on our list of best subscriptions you can give as gifts . Maybe your loved one who loves to host dinner parties could use some tips from Gordon Ramsay. There are three subscription tiers for MasterClass that each differ only in how many devices they allow at one time, and whether offline videos are supported. The Standard subscription only supports one device, whereas the Plus subscription allows two. These are normally $10 and $15 per month, respectively, and neither offers offline mode. The Premium tier, which carries a regular price of $20 per month, allows up to six devices and features offline mode for downloaded classes. All three tiers are part of the 40 percent off sale, which marks them down to $6, $9 and $12 respectively. MasterClass bills annually, so be sure to calculate the total from the "monthly" price before deciding. Follow @EngadgetDeals on X for the latest tech deals and buying advice .
Yahoo
a day ago
- Yahoo
ASX Penny Stocks Spotlight: Archer Materials And Two More Top Picks
As the Australian market wraps up a week of modest gains, investors are reflecting on the Reserve Bank's recent rate cut and its limited impact on trading sentiment. In this context, penny stocks—often smaller or newer companies—remain an intriguing option for those looking to explore beyond the more established names. While the term might seem outdated, these stocks continue to offer potential value through affordability and growth opportunities when backed by solid financials. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.33 A$109.91M ★★★★★★ GTN (ASX:GTN) A$0.39 A$74.36M ★★★★★★ IVE Group (ASX:IGL) A$2.95 A$454.84M ★★★★★☆ West African Resources (ASX:WAF) A$2.73 A$3.11B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.99 A$526.17M ★★★★★★ Regal Partners (ASX:RPL) A$3.08 A$1.04B ★★★★★★ Bravura Solutions (ASX:BVS) A$1.91 A$856.25M ★★★★★★ Austco Healthcare (ASX:AHC) A$0.355 A$129.75M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$4.50 A$213.53M ★★★★★★ CTI Logistics (ASX:CLX) A$1.795 A$144.58M ★★★★☆☆ Click here to see the full list of 454 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Archer Materials Simply Wall St Financial Health Rating: ★★★★★★ Overview: Archer Materials Limited is an Australian technology company focused on developing and commercializing semiconductor devices and sensors for quantum computing and medical diagnostics, with a market cap of A$89.20 million. Operations: The company generates revenue from its Materials Technology Research and Development segment, amounting to A$2.31 million. Market Cap: A$89.2M Archer Materials, with a market cap of A$89.20 million, is pre-revenue and currently unprofitable, generating limited revenue of A$2.31 million from its R&D segment. The company benefits from a strong liquidity position, with short-term assets (A$18.9M) surpassing both short-term (A$621.4K) and long-term liabilities (A$29K), and is debt-free for the past five years. While earnings have declined at 18.3% annually over the past five years, Archer maintains a stable cash runway exceeding three years based on current free cash flow levels without significant shareholder dilution recently observed. Navigate through the intricacies of Archer Materials with our comprehensive balance sheet health report here. Assess Archer Materials' previous results with our detailed historical performance reports. Genesis Minerals Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Genesis Minerals Limited is involved in the exploration, production, and development of gold deposits in Western Australia, with a market cap of A$4.77 billion. Operations: The company generates revenue of A$561.40 million from its mineral production, exploration, and development activities in Western Australia. Market Cap: A$4.77B Genesis Minerals, with a market cap of A$4.77 billion, has recently achieved profitability and boasts high-quality earnings. The company's debt is well-covered by operating cash flow, and it holds more cash than total debt, indicating strong financial health. Short-term assets comfortably exceed both short-term and long-term liabilities. Despite a relatively new board with an average tenure of 2.8 years, recent executive changes include the appointment of Jane Macey as Non-Executive Director, bringing over 20 years of industry experience. Genesis trades slightly below its estimated fair value and maintains stable weekly volatility at 6%. Unlock comprehensive insights into our analysis of Genesis Minerals stock in this financial health report. Understand Genesis Minerals' earnings outlook by examining our growth report. Pantoro Gold Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Pantoro Gold Limited, with a market cap of A$1.69 billion, is involved in gold mining, processing, and exploration activities in Western Australia through its subsidiaries. Operations: The company generates revenue from its Norseman Gold Project, amounting to A$289.11 million. Market Cap: A$1.69B Pantoro Gold Limited, with a market cap of A$1.69 billion, remains unprofitable but has a solid financial position with short-term assets (A$128.9M) exceeding both short and long-term liabilities. The company has more cash than total debt and maintains a sufficient cash runway for over three years, even as its free cash flow shrinks by 23.6% annually. Despite increasing losses over the past five years at 32% per year, earnings are forecast to grow significantly at 58.69% per year. The management team is experienced with an average tenure of 10.8 years, providing stability amid financial challenges. Click here to discover the nuances of Pantoro Gold with our detailed analytical financial health report. Examine Pantoro Gold's earnings growth report to understand how analysts expect it to perform. Key Takeaways Reveal the 454 hidden gems among our ASX Penny Stocks screener with a single click here. Ready To Venture Into Other Investment Styles? Outshine the giants: these 18 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AXE ASX:GMD and ASX:PNR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
